réservé à la recherche

Favipiravir (T-705) Inhibiteur de l'ARN polymérase

N° Cat.S7975

Le Favipiravir (T-705) est un inhibiteur puissant et sélectif de l'ARN polymérase dépendante de l'ARN, utilisé pour traiter les infections par le virus influenza.

Favipiravir (T-705) DNA/RNA Synthesis inhibiteur Chemical Structure

Structure chimique

Poids moléculaire: 157.1

Aller à

Contrôle qualité

Lot : Pureté : 99.97%

99.97

Cibles apparentées	HDAC PARP ATM/ATR DNA-PK WRN Topoisomerase PPAR Sirtuin Casein Kinase eIF
Autre DNA/RNA Synthesis Inhibiteurs	CX-5461 (Pidnarulex) B02 SCR7 EED226 RK-33 BMH-21 Triapine (3-AP) Carmofur YK-4-279 Halofuginone

Culture cellulaire, traitement et concentration de travail

Lignées cellulaires	Type dessai	Concentration	Temps dincubation	Description de lactivité	PMID
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-, Influenza A virus (A/Ann Arbor/6/1960(H2N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 0.38 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant , Influenza A virus (A/New York/34/2008(H1N1)) harboring M2 L26I mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysi, EC50 = 0.19 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant,Influenza A virus (A/Florida/01/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis, EC50 = 0.45 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against, adamantane-resistant Influenza B virus B/Memphis/20/1996 harboring neuraminidase R152K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic ana, EC50 = 0.57 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-， Influenza A virus (A/Swine/South Dakota/03/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet, EC50 = 0.83 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-susceptible ,Influenza A virus (A/Brazil/1633/2008(H1N1)) harboring neuraminidase Q136K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros, EC50 = 0.83 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant,Influenza A virus (A/pdm/California/05/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros, EC50 = 0.83 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant,Influenza A virus (A/pdm/New York/18/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsco, EC50 = 0.89 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-, Influenza A virus (A/turkey/Minnesota/833/1980(H4N2)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days , EC50 = 0.89 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-, Influenza A virus (A/turkey/Minnesota/833/1980(H4N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet , EC50 = 0.96 μM.	20350949
MDCK	Antiviral assay			Antiviral activity against, adamantane-resistant Influenza A virus (A/Bethesda/956/2006(H3N2)) harboring neuraminidase R292K mutant and M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication af, EC50 = 1.21 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant ,Influenza A virus (A/pdm/Mexico/4604/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsco, EC50 = 1.21 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant,Influenza B virus B/Memphis/20/1996 infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 1.21 μM.	20350949
MDCK	Antiviral assay			Antiviral activity against adamantane，Influenza A virus (A/chicken/Vietnam/NCVD103/2007 clade 2.3.4 (H5N1)) harboring neuraminidase I222T mutant infected in MDCK cells assessed as inhibition of viral replication after, EC50 = 1.27 μM.	20350949
MDCK	Antiviral assay			Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by virus yield reduction assay, EC90 = 1.3 μM.	17194832
MDCK	Antiviral assay		1 hr	Antiviral activity against Influenza B virus (B/Brisbane/60/2008) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis, EC50 = 1.32 μM.	23419738
MDCK	Antiviral assay			Antiviral activity against adamantane-, Influenza A virus (A/Vietnam/HN30408/2005 N294S clade 1 (H5N1)) harboring M2 L26I, S31N mutant and neuraminidase N294S mutant infected in MDCK cells assessed as inhibition of viral , EC50 = 1.341 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant,Influenza A virus (A/pdm/California/07/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros, EC50 = 1.4 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant,Influenza B virus (B/Rochester/01/2001) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 1.4 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-， Influenza A virus (A/Georgia/17/2006(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 1.46 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-,Influenza A virus (A/turkey/VA/4529/2002 (H7N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 1.53 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-,Influenza A virus (A/Florida/21/2008(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsc, EC50 = 1.59 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-，Influenza A virus (A/duck/Vietnam/NCVD93/2007 clade 2.3.4 (H5N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using cry, EC50 = 1.59 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against, adamantane-resistant Influenza B virus (B/Rochester/01/2001) harboring neuraminidase D198N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic, EC50 = 1.72 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-, Influenza A virus (A/Brazil/1067/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 1.85 μM.	20350949
MDCK	Antiviral assay		1 hr	Antiviral activity against Influenza B virus (B/Lee/40) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis, EC50 = 1.93 μM.	23419738
MDCK	Antiviral assay		1 hr	Antiviral activity against Influenza B virus (B/Panama/45/1990) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis, EC50 = 1.94 μM.	23419738
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant，Influenza A virus (A/pdm/California/04/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros, EC50 = 1.97 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-,Influenza A virus (A/swine/Michigan/09/2007 (H1N2)) harboring M2 V27I, V28D mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic a, EC50 = 2.23 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-,Influenza A virus (A/Ecuador/5179/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 2.48 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-,Influenza A virus (A/Georgia/20/2006(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsc, EC50 = 2.55 μM.	20350949
MDCK	Antiviral assay			Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay, EC50 = 2.6 μM.	17194832
MDCK	Antiviral assay			Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by virus yield reduction assay, EC90 = 2.6 μM.	17194832
MDCK	Antiviral assay		24 hrs	Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in MDCK cells assessed as inhibition of neuraminidase activity using 2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid substrate pretreated with cells for 24 hrs followed by vira, EC50 = 2.7 μM.	27120583
MDCK	Antiviral assay		1 hr	Antiviral activity against Influenza B virus (B/Taiwan/2/62) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis, EC50 = 2.84 μM.	23419738
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant,Influenza A virus (A/Wisconsin/16/2008(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros, EC50 = 2.87 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-, Influenza A virus (A/Idaho/01/2009(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysi, EC50 = 2.93 μM.	20350949
MDCK	Antiviral assay			Antiviral activity against, adamantane-resistant Influenza A virus (A/Luhansk/18/2008(H1N1)) harboring neuraminidase H274Y mutant and M2 G34E mutant infected in MDCK cells assessed as inhibition of viral replication afte, EC50 = 2.93 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-,Influenza B virus (B/Illinois/03/2008) harboring neuraminidase E119A mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis u, EC50 = 3 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-,Influenza A virus (A/Washington/10/2008(H1N1)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic anal, EC50 = 3.25 μM.	20350949
MDCK	Antiviral assay			Antiviral activity against adamantane-susceptible , Influenza A virus (A/duck/Vietnam/NCVD94/2007 clade 2.3.4 (H5N1)) harboring neuraminidase I117V mutant infected in MDCK cells assessed as inhibition of viral replication a, EC50 = 3.38 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-,Influenza A virus (A/California/27/2007(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 3.63 μM.	20350949
MDCK	Antiviral assay			Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by virus yield reduction assay, EC90 = 3.8 μM.	17194832
MDCK	Antiviral assay			Antiviral activity against, adamantane-resistant Influenza A virus (A/Texas/12/2007 (clone)(H3N2)) harboring neuraminidase E119I mutant and harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral , EC50 = 3.95 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant, Influenza B virus (B/Illinois/47/2005) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 4.01 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant,Influenza A virus (A/New Hampshire/01/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic an, EC50 = 4.08 μM.	20350949
MDCK	Antiviral assay			Antiviral activity against, adamantane-resistant Influenza A virus (A/Vietnam/HN30408/2005 H274Y clade 1 (H5N1)) harboring M2 L26I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition, EC50 = 4.14 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant,Influenza A virus (A/Massachusetts/03/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic an, EC50 = 4.2 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant,Influenza A virus (A/Washington/01/2007(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analy, EC50 = 4.46 μM.	20350949
MDCK	Antiviral assay			Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by neutral red uptake assay, EC50 = 4.5 μM.	17194832
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-,Influenza A virus (A/Swine/Texas/14/2008 (H1N1)) harboring M2 V27T, V28D mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic anal, EC50 = 4.52 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-susceptible,Influenza A virus (A/Santiago/5248/2008(H1N1)) harboring neuraminidase D198E mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micr, EC50 = 4.7 μM.	20350949
MDCK	Antiviral assay		1 hr	Antiviral activity against Influenza A virus (A/Hong kong/8/1968(H2N3)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis, EC50 = 4.71 μM.	23419738
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-,Influenza A virus (A/New Jersey/15/2007(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micr, EC50 = 4.9 μM.	20350949
Vero	Antiviral assay		7 to 8 days	Antiviral activity against Junin virus Candid-1 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days, EC50 = 5 μM.	17606691
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-,Influenza A virus (A/North Carolina/02/ 2009(H1N1)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic, EC50 = 5.03 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against, adamantane-resistant Influenza B virus (B/Michigan/20/2005) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic , EC50 = 5.03 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant,Influenza A virus (A/Vietnam/1203/2004 clade 1 (H5N1)) harboring M2 L26I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by mic, EC50 = 5.22 μM.	20350949
MDCK	Antiviral assay			Antiviral activity agains, adamantane-resistant Influenza A virus (A/Texas/12/2007 (clone)(H3N2)) harboring neuraminidase E119V mutant and harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral , EC50 = 5.22 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant Influenza B virus (B/New York/22/2008) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 5.3 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against, adamantane-resistant Influenza A virus (A/Wuhan/395/1995-like (H3N2)) harboring neuraminidase E119V mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by mi, EC50 = 5.41 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant, Influenza A virus (A/Wuhan/395/1995-like (H3N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal viole, EC50 = 5.99 μM.	20350949
Vero	Antiviral assay		7 to 8 days	Antiviral activity against Pichinde virus An 4763 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days, EC50 = 6 μM.	17606691
Vero	Antiviral assay		7 to 8 days	Antiviral activity against Tacaribe virus TRVL11573 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days, EC50 = 6 μM.	17606691
MDCK	Antiviral assay			Antiviral activity against, adamantane-resistant Influenza A virus (A/pdm/Washington/29/2009 (H1N1)) harboring M2 V28I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral re, EC50 = 6.62 μM.	20350949
MDCK	Antiviral assay	1 hr	3 days	Antiviral activity against Influenza A virus (A/Taiwan/1/1986(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis, EC50 = 6.95 μM.	23419738
MDCK	Antiviral assay			Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by virus yield reduction assay, EC90 = 7.7 μM.	17194832
MDCK	Antiviral assay		3 days	Antiviral activity against Influenza virus B/Ned/537/05 infected in MDCK cells assessed as reduction in viral replication at 3 days post infection by formazan-based MTS assay, EC50 = 8.3 μM.	29906392
MDCK	Antiviral assay		3 days	Antiviral activity against Influenza virus B/Ned/537/05 infected in MDCK cells assessed as reduction in viral replication at 3 days post infection by microscopic analysis, EC50 = 9 μM.	29906392
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant,Influenza A virus (A/New York/107/2003(H7N2)) harboring M2 V28A, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic , EC50 = 10.2 μM.	20350949
MDCK	Antiviral assay			Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by neutral red uptake assay, EC50 = 11.5 μM.	17194832
MDCK	Antiviral assay			Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay, EC50 = 12.1 μM.	17194832
Vero-A	Antiviral assay			Antiviral activity against Chikungunya virus venturini isolate (Italy 2008) infected in African green monkey Vero-A cells assessed as inhibition of viral-induced cytopathic effect measured on day 7 post infection by MTS/PMS assay, EC50 = 16 μM.	28689975
MDCK	Antiviral assay			Antiviral activity against oseltamivir-susceptible, adamantane-resistant Influenza A virus (A/pdm/Illinois/10/2009(H1N1)) harboring M2 V28I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral repli, EC50 = 22.48 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against Influenza virus A/X-31 infected in MDCK cells assessed as reduction in viral replication at 3 days post infection by microscopic analysis, EC50 = 24 μM.	29906392
Vero-A	Antiviral assay			Antiviral activity against Chikungunya virus 899 infected in African green monkey Vero-A cells assessed as inhibition of viral-induced cytopathic effect measured on day 7 post infection by MTS/PMS assay, EC50 = 25 μM.	28689975
Vero-A	Antiviral assay			Antiviral activity against Chikungunya virus LR2006-OPY1 infected in African green monkey Vero-A cells assessed as inhibition of viral-induced cytopathic effect measured on day 7 post infection by MTS/PMS assay, EC50 = 25 μM.	28689975
MDCK	Antiviral assay		3 days	Antiviral activity against Influenza virus A/X-31 infected in MDCK cells assessed as reduction in viral replication at 3 days post infection by formazan-based MTS assay, EC50 = 26 μM.	29906392
MDCK	Antiviral assay			Antiviral activity against 0.001 MOI adamantane-resistant,oseltamivir-susceptible Influenza A virus (A/pdm/Mexico/4604/2009(H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as determination of viral titer in cell culture at, NULL = NULL μM.	20350949
MDCK	Antiviral assay			Antiviral activity against 0.001 MOI adamantane-resistant,oseltamivir-susceptible Influenza A virus (A/pdm/California/04/2009(H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as determination of viral titer in cell culture , NULL = NULL μM.	20350949
MDCK	Antiviral assay	128 uM		Antiviral activity against adamantane-resistant,oseltamivir-susceptible Influenza A virus (A/pdm/Mexico/4604/2009(H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as determination of viral titer in cell culture at 128 uM af, NULL = NULL μM.	20350949
MDCK	Antiviral assay	128 uM		Antiviral activity against adamantane-resistant,oseltamivir-susceptible Influenza A virus (A/pdm/California/04/2009(H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as determination of viral titer in cell culture at 128 uM , NULL = NULL μM.	20350949
Vero	Antiviral assay	6400 uM	up to 12 hrs	Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as time required for inhibition of viral replication at 6400 uM up to 12 hrs post-viral infection, NULL = NULL μM.	18955536
MDCK	Antiviral assay		0 to 2 hrs	Inhibition of influenza A virus infected in MDCK cells assessed as inhibition of viral load treated with compound at 0 to 2 hrs post-infection by RT-qPCR method based time of addition assay, NULL = NULL μM.	30192544
MDCK	Antiviral assay		5 to 8 hrs	Inhibition of influenza A virus infected in MDCK cells assessed as inhibition of viral load treated with compound at 5 to 8 hrs post-infection by RT-qPCR method based time of addition assay, NULL = NULL μM.	30192544
MDCK	Antiviral assay		0 to 10 hrs	Inhibition of influenza A virus infected in MDCK cells assessed as inhibition of viral load treated with compound at 0 to 10 hrs post-infection by RT-qPCR method based time of addition assay, NULL = NULL μM.	30192544
MDCK	Antiviral assay		2 to 5 hrs	Inhibition of influenza A virus infected in MDCK cells assessed as inhibition of viral load treated with compound at 2 to 5 hrs post-infection by RT-qPCR method based time of addition assay, NULL = NULL μM.	30192544
MDCK	Antiviral assay	10 uM	up to 8 hrs	Antiviral activity against Influenza A virus (A/chicken/Hubei/327/2004(H5N1)) infected in MDCK cells assessed as inhibition of early stages of viral replication at 10 uM up to 8 hrs by crystal violet staining based plaque reduction assay dependent time-of, NULL = NULL μM.	30292897
MDCK	Antiviral assay	100 uM	12 hrs	Antiviral activity against Influenza virus A/X-31 infected in MDCK cells assessed as inhibition of one cycle viral RNA synthesis at 100 uM preincubated with cells for 12 hrs followed by viral infection measured after 10 hrs post infection by RT-qPCR metho, NULL = NULL μM.	29906392
MDCK	Antiviral assay	250 uM	10 hrs	Antiviral activity against Influenza virus A/X-31 infected in MDCK cells assessed as inhibition of one cycle viral RNA sytheis at 250 uM added together with virus and measured at 10 hrs post infection by RT-qPCR method, NULL = NULL μM.	29906392
Cliquez pour voir plus de données expérimentales sur les lignées cellulaires

Informations chimiques, stockage et stabilité

Poids moléculaire	157.1	Formule	C₅H₄FN₃O₂	Stockage (À partir de la date de réception)	3 ans-20°Cpoudre
N° CAS	259793-96-9	Télécharger le SDF		Stockage des solutions mères	1 an-80°Cen solvant 1 mois-20°Cen solvant
Synonymes	N/A			Smiles	C1=C(N=C(C(=O)N1)C(=O)N)F

Solubilité

In vitro
Lot:

DMSO : 31 mg/mL (197.32 mM)
(Le DMSO contaminé par lhumidité peut réduire la solubilité. Utiliser du DMSO frais et anhydre.)

Water : 2 mg/mL

Ethanol : 2 mg/mL

Calculateur de molarité

Masse	Concentration	Volume	Poids moléculaire
=	×	×

Calculateur de dilution Calculateur de poids moléculaire

In vivo Lot:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validé par les laboratoires Selleck. Si vous avez besoin dajustements à cette formulation, contactez notre équipe de vente pour des tests personnalisés.	1.550mg/ml (9.87mM)	Taking the 1 mL working solution as an example, add 50 μL of 31 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validé par les laboratoires Selleck. Si vous avez besoin dajustements à cette formulation, contactez notre équipe de vente pour des tests personnalisés.	1.550mg/ml (9.87mM)	Taking the 1 mL working solution as an example, add 50 μL of 31 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

Calculateur de formulation in vivo (Solution claire)

Étape 1 : Entrez les informations ci-dessous (Recommandé : Un animal supplémentaire pour tenir compte des pertes pendant lexpérience)

Dosage : mg/kg Poids moyen des animaux : g Volume de dosage par animal :μL Nombre danimaux :

Étape 2 : Entrez la formulation in vivo (Ceci nest que le calculateur, pas la formulation. Veuillez nous contacter dabord sil ny a pas de formulation in vivo dans la section Solubilité.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Résultats du calcul :

Concentration de travail : mg/ml;

Méthode de préparation du liquide maître DMSO : mg médicament prédissous dans μL DMSO ( Concentration du liquide maître mg/mL, Veuillez nous contacter dabord si la concentration dépasse la solubilité du DMSO du lot de médicament. )

Méthode de préparation de la formulation in vivo : Prendre μL DMSO liquide maître, ajouter ensuiteμL PEG300, mélanger et clarifier, ajouter ensuiteμL Tween 80, mélanger et clarifier, ajouter ensuite μL ddH₂O, mélanger et clarifier.

Méthode de préparation de la formulation in vivo : Prendre μL DMSO liquide maître, ajouter ensuite μL Huile de maïs, mélanger et clarifier.

Remarque : 1. Assurez-vous que le liquide est clair avant dajouter le solvant suivant.
2. Assurez-vous dajouter le(s) solvant(s) dans lordre. Vous devez vous assurer que la solution obtenue lors de lajout précédent est une solution claire avant de procéder à lajout du solvant suivant. Des méthodes physiques telles que le vortex, les ultrasons ou le bain-marie peuvent être utilisées pour faciliter la dissolution.

Mécanisme daction

Targets/IC₅₀/Ki	RNA-dependent RNA polymerase
In vitro	Le Favipiravir (T-705) montre des activités anti-influenza virus avec une CI50 allant de 0,013 à 0,48 μg/ml pour les virus influenza A, de 0,039 à 0,089 μg/ml pour les virus influenza B, et de 0,030 à 0,057 μg/ml pour les virus influenza C. Dans les lignées cellulaires mammaliennes (cellules MDCK, cellules Vero, cellules HEL, cellules A549, cellules HeLa et cellules HEp-2), il ne montre aucune cytotoxicité à des concentrations allant jusqu'à 1 000 μg/ml. Dans les cellules MDCK inoculées avec des virus influenza A (H1N1) saisonniers, ce composé induit une mutagenèse létale.
In vivo	Le Favipiravir (T-705) protège les souris infectées par le virus influenza de la mort lorsqu'il est administré à raison de 200 mg/kg/jour (p.o.). Chez des souris expérimentalement infectées par le virus Ebola, ce composé bloque efficacement la production virale, atteignant une efficacité antivirale de 95 % et 99,6 % à 2 et 6 jours après le début du traitement, respectivement.
Références	[1] https://pubmed.ncbi.nlm.nih.gov/11897578/ [2] https://pubmed.ncbi.nlm.nih.gov/23325689/ [3] https://pubmed.ncbi.nlm.nih.gov/26343011/

Applications

Méthodes	Biomarqueurs	PMID
Growth inhibition assay	Survival Cell viability	26711718
IHC	H&E Staining NiV nucleoprotein LASV antigen H&E stain	29765101
Immunofluorescence	rNiV-Gluc	29765101

Informations sur lessai clinique

(données de https://clinicaltrials.gov, mis à jour le 2024-05-22)

Numéro NCT	Recrutement	Conditions	Sponsor/Collaborateurs	Date de début	Phases
NCT06024421	Recruiting	Infectious Disease\|Pharmacology	Institut National de la Santé Et de la Recherche Médicale France\|FUJIFILM Toyama Chemical Co. Ltd.	April 2024	Phase 1
NCT05940545	Recruiting	CCHF	Liverpool School of Tropical Medicine	July 12 2023	Phase 1\|Phase 2
NCT04907682	Completed	Lassa Fever	Bernhard Nocht Institute for Tropical Medicine\|University of Hamburg-Eppendorf\|Alliance for International Medical Action\|Institut National de la Santé Et de la Recherche Médicale France\|University of Bordeaux\|Federal Medical Centre Owo\|Irrua Specialist Teaching Hospital	July 30 2021	Phase 2

Support technique

Instructions de manipulation

Tel: +1-832-582-8158 Ext:3

Si vous avez dautres questions, veuillez laisser un message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):